This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MedTech Thrives on Healthcare IT in 2021: 4 Stocks to Focus on
by Debanjana Dey
Health IT stocks like HealthEquity (HQY), Veeva Systems (VEEV), Tabula Rasa (TRHC) and Allscripts (MDRX) are expected to continue their run over the next few months.
3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19
by Riya Anand
Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.
The Zacks Analyst Blog Highlights: Boyd Gaming, International Game Technology, Allscripts Healthcare, Zoom Video and Thryv Holdings
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boyd Gaming, International Game Technology, Allscripts Healthcare, Zoom Video and Thryv Holdings
Invest in 3 Top-Performing Sectors for Gains in 2H21
by Urmimala Biswas
Amid the current market incongruity, investors should definitely invest in the best- performing sectors for secure gains ahead.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
Allscripts' (MDRX) Unit Inks Deal to Boost Clinical Research
by Zacks Equity Research
Allscripts' (MDRX) unit, Veradigm, enters into a strategic partnership with PRA Health (PRAH) to expand patients' access to clinical research.
Digital Health Momentum is Here to Stay: 3 MedTech Stocks in Focus
by Trina Mukherjee
Here we look at three stocks, MDRX, CERN and RMD, that investors can keep a watch on the back of their robust digital health prospects.
3 Stocks With Telehealth Offerings for Post-Pandemic Gains
by Riya Anand
Stocks like CVS Health (CVS), Walgreens Boots Alliance (WBA) and Allscripts (MDRX) are expected to continue to grow post-pandemic on a series of remote health care product and service launches.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and solid prospects of the Sunrise EHR platform.
Allscripts (MDRX), Lash Group Team Up for Better Patient Care
by Zacks Equity Research
Allscripts' (MDRX) Veradigm enters collaboration to streamline specialty medication management for medical clinics and practices across the nation.